Notice2022-06174
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 24, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 57 (Thursday, March 24, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 57 (Thursday, March 24, 2022)]
[Notices]
[Page 16757]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-06174]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
<a href="/cdn-cgi/l/email-protection#58283d2c3d2a762c2d363f18363130763f372e"><span class="__cf_email__" data-cfemail="c9b9acbdacbbe7bdbca7ae89a7a0a1e7aea6bf">[email protected]</span></a>. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows:
Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens
and Their Use
Description of Technology
Using a computational design methodology, SARS-CoV-2 spike proteins
containing engineered amino acid changes to the receptor binding domain
(RBD) were designed. These engineered spike proteins improved the
immune response upon immunization of animals. An engineered RBD was
also expressed at greater yield, had increased temperature stability,
and improved the immune response upon immunization of animals.
Specifically, the disclosed RBD designs can be produced approximately 7
times more efficiently than the native sequence, facilitating vaccine
manufacturing on a global scale. The disclosed designs also have up to
10 [deg]C higher thermal stability than the native sequence, suggesting
enhanced stability during storage and when in the body. Finally,
immunization of animals with the disclosed antigens produces up to 10-
fold higher levels of blocking antibodies than the native sequence and
30-fold higher levels of pseudoviral neutralizing antibodies. An
additional RBD protein has been engineered to eliminate the need for
glycosylation, facilitating production and single-component
nanoparticle display of the antigen. The engineered receptor binding
domain (RBD) and spike protein antigens produce significant
improvements in pre-clinical animal models and may be used to develop
improved coronavirus vaccines.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Novel SARS-CoV-2 vaccine.
<bullet> Improved SARS-CoV-2 diagnostics using stabilized antigens.
<bullet> Method of designing vaccine candidates or stabilized
antigens by computational. optimization of amino acid identity,
followed by additional sequence comparison and selection (Stabilizer
for Protein Expression and Epitope Design (SPEEDesign)).
Competitive Advantages
<bullet> Novel SARS-CoV-2 spike vaccine with improved breadth and
duration of protection.
<bullet> Novel RBD monomer and nanoparticle designs that are more
immunogenic and stable than the naturally occurring RBD sequence.
<bullet> Computational method of designing vaccine antigens.
Development Stage
<bullet> Pre-clinical testing of the novel immunogens in non-human
primates.
Inventors: Dr. Niraj Tolia and Dr. Thayne Dickey, both of NIAID.
Publications: ``Design of the SARS-CoV-2 RBD vaccine antigen
improves neutralizing antibody response'', <a href="https://doi.org/10.1101/2021.05.09.443238">https://doi.org/10.1101/2021.05.09.443238</a>.
Intellectual Property: HHS Reference No. E-045-2021-0-US-01--U.S.
Provisional Application No. 63/200,194, filed February 18, 2021; PCT/
US2022/070744, filed February 1, 2022
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or <a href="/cdn-cgi/l/email-protection#b6c6d3c2d3c498c2c3d8d1f6d8dfde98d1d9c0"><span class="__cf_email__" data-cfemail="9eeefbeafbecb0eaebf0f9def0f7f6b0f9f1e8">[email protected]</span></a>.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize the invention. For collaboration
opportunities, please contact Peter Tung at 240-669-5483;
<a href="/cdn-cgi/l/email-protection#b1c1d4c5d4c39fc5c4dfd6f1dfd8d99fd6dec7"><span class="__cf_email__" data-cfemail="2c5c4958495e025859424b6c424544024b435a">[email protected]</span></a>.
Dated: March 17, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-06174 Filed 3-23-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 24, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.